Investec Bank Disclosure in AMS Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 19 2026
0mins
Source: Yahoo Finance
- Trading Disclosure: On June 18, 2026, Investec Bank disclosed its dealings related to Advanced Medical Solutions Group Plc, highlighting its role as an advisor and joint broker, which underscores its significance in the company.
- Securities Trading Details: Investec Bank purchased 109,174 ordinary shares at a highest price of £229 and a lowest price of £227, while selling 59,174 shares, indicating its active trading behavior in the market.
- No Other Trading Disclosures: The bank did not disclose dealings related to any other parties in this transaction, indicating a focused approach on its dealings with Advanced Medical Solutions Group Plc.
- Compliance and Transparency: This disclosure adheres to Rule 8 of the Takeover Code, ensuring that market participants have access to necessary information for informed decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMS
About AMS
American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investec Bank Disclosure in AMS Trading
- Trading Disclosure: On June 18, 2026, Investec Bank disclosed its dealings related to Advanced Medical Solutions Group Plc, highlighting its role as an advisor and joint broker, which underscores its significance in the company.
- Securities Trading Details: Investec Bank purchased 109,174 ordinary shares at a highest price of £229 and a lowest price of £227, while selling 59,174 shares, indicating its active trading behavior in the market.
- No Other Trading Disclosures: The bank did not disclose dealings related to any other parties in this transaction, indicating a focused approach on its dealings with Advanced Medical Solutions Group Plc.
- Compliance and Transparency: This disclosure adheres to Rule 8 of the Takeover Code, ensuring that market participants have access to necessary information for informed decision-making.
See More
CANACCORD GENUITY Discloses Shareholding Information
- Shareholding Disclosure: CANACCORD GENUITY WEALTH LIMITED holds 9,856,995 shares in ADVANCED MEDICAL SOLUTIONS GROUP PLC, representing 4.4716% of total shares, indicating a significant investment position that may influence market confidence in the company.
- Trading Activity Overview: In recent transactions, CANACCORD GENUITY sold multiple stock lots, including 2,260 shares at 220.5 pence each and 10,000 shares at 224 pence, reflecting its active market participation and liquidity management strategy.
- Compliance Information: This disclosure adheres to Rule 8.3 of the Takeover Code, ensuring transparency and compliance, which may enhance investor trust in the company's operations and governance.
- Future Outlook: Although the current shareholding is relatively low, CANACCORD GENUITY's ongoing disclosures and trading activities may provide a basis for its future investment strategy in ADVANCED MEDICAL SOLUTIONS GROUP PLC, potentially influencing subsequent decisions.
See More
CANACCORD GENUITY Discloses Shareholding Information
- Shareholding Disclosure: CANACCORD GENUITY WEALTH LIMITED holds 9,934,831 shares in ADVANCED MEDICAL SOLUTIONS GROUP PLC, representing 4.5071% of the total share capital, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: In its latest transaction, the firm purchased 1,250 shares of 5p ordinary stock at a price of 213.8458 pence per share, indicating ongoing investment interest that may influence market perceptions of the stock.
- Disclosure Date: This disclosure was made on June 3, 2026, reflecting the company's commitment to transparency during the acquisition process and adherence to regulations to maintain investor confidence.
- Compliance and Regulation: The disclosure follows the requirements of the Takeover Code, ensuring timely reporting of all relevant securities holdings, thereby enhancing market trust in the company's compliance efforts.
See More
American Shared Hospital Services to Hold Annual Shareholders Meeting
- Annual Meeting Announcement: American Shared Hospital Services will hold its Annual Shareholders Meeting on June 24, 2026, at 9:00 AM CT, conducted via live audio webcast, enhancing shareholder engagement and transparency.
- Virtual Meeting Format: The meeting will be entirely virtual with no physical location, requiring shareholders to use a 16-digit control number from their proxy card to participate, reflecting the company's commitment to digital transformation.
- Shareholder Eligibility Confirmation: The Board has set April 27, 2026, as the record date for determining shareholders entitled to vote, ensuring that only registered shareholders can participate, thereby strengthening shareholder rights.
- Increased Business Transparency: Items of business to be discussed will be available in the company's 2026 proxy statement, further enhancing governance transparency and shareholders' awareness of corporate decisions.
See More
American Shared Hospital Services Q1 2026 Earnings Insights
- Leadership Transition: In late April, the company announced CEO Gary Delanois's resignation for personal reasons, with Craig Tagawa appointed as Interim CEO, which may influence the company's strategic direction and execution capabilities.
- Significant Revenue Growth: Q1 2026 total revenue increased by 15.9% year-over-year to $7.1 million, surpassing analysts' estimates of $6.87 million, indicating strong contributions from Rhode Island and Puebla radiation therapy centers, thus enhancing the company's competitive position in the market.
- International Market Opportunities: Management highlighted the expected operational launch of the Guadalajara Center later this year, reflecting the company's focus on international market expansion, which could provide new revenue growth drivers in the future.
- Improved Cash Flow Position: By the end of the quarter, the company reported cash and cash equivalents of $5.2 million, a significant increase from $3.7 million at year-end, indicating improved financial health in operations and enhancing flexibility for future investments and expansions.
See More
American Shared Hospital Q1 Earnings Report
- Earnings Highlights: American Shared Hospital reported a Q1 GAAP EPS of -$0.09, indicating a loss; however, revenue increased by 15.9% year-over-year to $7.1 million, demonstrating the company's resilience and growth potential in the market.
- Adjusted EBITDA Growth: The adjusted EBITDA rose to $1.1 million from $0.9 million in the prior year quarter, reflecting an 18.4% increase that indicates significant progress in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $5.2 million, a substantial increase from $3.7 million at December 31, 2025, enhancing the company's financial stability and capacity for future investments.
- Future Development Plans: The company is set to launch its Bristol facility in late 2027 and plans to establish a Rhode Island proton center in 2028, showcasing its long-term strategic positioning and intent to expand in the healthcare services sector.
See More
Investec Bank Disclosure in AMS Trading
- Trading Disclosure: On June 18, 2026, Investec Bank disclosed its dealings related to Advanced Medical Solutions Group Plc, highlighting its role as an advisor and joint broker, which underscores its significance in the company.
- Securities Trading Details: Investec Bank purchased 109,174 ordinary shares at a highest price of £229 and a lowest price of £227, while selling 59,174 shares, indicating its active trading behavior in the market.
- No Other Trading Disclosures: The bank did not disclose dealings related to any other parties in this transaction, indicating a focused approach on its dealings with Advanced Medical Solutions Group Plc.
- Compliance and Transparency: This disclosure adheres to Rule 8 of the Takeover Code, ensuring that market participants have access to necessary information for informed decision-making.
See More
CANACCORD GENUITY Discloses Shareholding Information
- Shareholding Disclosure: CANACCORD GENUITY WEALTH LIMITED holds 9,856,995 shares in ADVANCED MEDICAL SOLUTIONS GROUP PLC, representing 4.4716% of total shares, indicating a significant investment position that may influence market confidence in the company.
- Trading Activity Overview: In recent transactions, CANACCORD GENUITY sold multiple stock lots, including 2,260 shares at 220.5 pence each and 10,000 shares at 224 pence, reflecting its active market participation and liquidity management strategy.
- Compliance Information: This disclosure adheres to Rule 8.3 of the Takeover Code, ensuring transparency and compliance, which may enhance investor trust in the company's operations and governance.
- Future Outlook: Although the current shareholding is relatively low, CANACCORD GENUITY's ongoing disclosures and trading activities may provide a basis for its future investment strategy in ADVANCED MEDICAL SOLUTIONS GROUP PLC, potentially influencing subsequent decisions.
See More
CANACCORD GENUITY Discloses Shareholding Information
- Shareholding Disclosure: CANACCORD GENUITY WEALTH LIMITED holds 9,934,831 shares in ADVANCED MEDICAL SOLUTIONS GROUP PLC, representing 4.5071% of the total share capital, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: In its latest transaction, the firm purchased 1,250 shares of 5p ordinary stock at a price of 213.8458 pence per share, indicating ongoing investment interest that may influence market perceptions of the stock.
- Disclosure Date: This disclosure was made on June 3, 2026, reflecting the company's commitment to transparency during the acquisition process and adherence to regulations to maintain investor confidence.
- Compliance and Regulation: The disclosure follows the requirements of the Takeover Code, ensuring timely reporting of all relevant securities holdings, thereby enhancing market trust in the company's compliance efforts.
See More
American Shared Hospital Services to Hold Annual Shareholders Meeting
- Annual Meeting Announcement: American Shared Hospital Services will hold its Annual Shareholders Meeting on June 24, 2026, at 9:00 AM CT, conducted via live audio webcast, enhancing shareholder engagement and transparency.
- Virtual Meeting Format: The meeting will be entirely virtual with no physical location, requiring shareholders to use a 16-digit control number from their proxy card to participate, reflecting the company's commitment to digital transformation.
- Shareholder Eligibility Confirmation: The Board has set April 27, 2026, as the record date for determining shareholders entitled to vote, ensuring that only registered shareholders can participate, thereby strengthening shareholder rights.
- Increased Business Transparency: Items of business to be discussed will be available in the company's 2026 proxy statement, further enhancing governance transparency and shareholders' awareness of corporate decisions.
See More
American Shared Hospital Services Q1 2026 Earnings Insights
- Leadership Transition: In late April, the company announced CEO Gary Delanois's resignation for personal reasons, with Craig Tagawa appointed as Interim CEO, which may influence the company's strategic direction and execution capabilities.
- Significant Revenue Growth: Q1 2026 total revenue increased by 15.9% year-over-year to $7.1 million, surpassing analysts' estimates of $6.87 million, indicating strong contributions from Rhode Island and Puebla radiation therapy centers, thus enhancing the company's competitive position in the market.
- International Market Opportunities: Management highlighted the expected operational launch of the Guadalajara Center later this year, reflecting the company's focus on international market expansion, which could provide new revenue growth drivers in the future.
- Improved Cash Flow Position: By the end of the quarter, the company reported cash and cash equivalents of $5.2 million, a significant increase from $3.7 million at year-end, indicating improved financial health in operations and enhancing flexibility for future investments and expansions.
See More
American Shared Hospital Q1 Earnings Report
- Earnings Highlights: American Shared Hospital reported a Q1 GAAP EPS of -$0.09, indicating a loss; however, revenue increased by 15.9% year-over-year to $7.1 million, demonstrating the company's resilience and growth potential in the market.
- Adjusted EBITDA Growth: The adjusted EBITDA rose to $1.1 million from $0.9 million in the prior year quarter, reflecting an 18.4% increase that indicates significant progress in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $5.2 million, a substantial increase from $3.7 million at December 31, 2025, enhancing the company's financial stability and capacity for future investments.
- Future Development Plans: The company is set to launch its Bristol facility in late 2027 and plans to establish a Rhode Island proton center in 2028, showcasing its long-term strategic positioning and intent to expand in the healthcare services sector.
See More
